NYSE - Nasdaq Real Time Price USD
Hims & Hers Health, Inc. (HIMS)
29.93 +1.66 (+5.87%)
As of 2:04:54 PM EDT. Market Open.
Trade HIMS on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for HIMS
- Previous Close
28.27 - Open
29.09 - Bid 30.26 x 40000
- Ask 30.28 x 30000
- Day's Range
28.55 - 30.39 - 52 Week Range
13.74 - 70.43 - Volume
27,814,647 - Avg. Volume
35,687,715 - Market Cap (intraday)
6.916B - Beta (5Y Monthly) 2.42
- PE Ratio (TTM)
58.69 - EPS (TTM)
0.51 - Earnings Date May 11, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
26.04
Recent News: HIMS
View More
Performance Overview: HIMS
Trailing total returns as of 5/11/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
HIMS
7.82%
S&P 500 (^GSPC)
8.50%
1-Year Return
HIMS
42.40%
S&P 500 (^GSPC)
31.22%
3-Year Return
HIMS
183.16%
S&P 500 (^GSPC)
79.81%
5-Year Return
HIMS
202.32%
S&P 500 (^GSPC)
78.88%
Earnings Trends: HIMS
View MoreAnalyst Insights: HIMS
View MoreStatistics: HIMS
View MoreValuation Measures
As of 5/8/2026
Market Cap
6.53B
Enterprise Value
7.08B
Trailing P/E
55.43
Forward P/E
66.67
PEG Ratio (5yr expected)
2.43
Price/Sales (ttm)
3.11
Price/Book (mrq)
12.08
Enterprise Value/Revenue
3.01
Enterprise Value/EBITDA
44.19
Financial Highlights
Profitability and Income Statement
Profit Margin
5.47%
Return on Assets (ttm)
5.29%
Return on Equity (ttm)
25.23%
Revenue (ttm)
2.35B
Net Income Avi to Common (ttm)
128.37M
Diluted EPS (ttm)
0.51
Balance Sheet and Cash Flow
Total Cash (mrq)
577.49M
Total Debt/Equity (mrq)
207.16%
Levered Free Cash Flow (ttm)
110.51M
Compare To: HIMS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
29.93
+5.87%
Mkt Cap 6.916B
Industry Drug Manufacturers—Specialty & Generic
28.20
-3.69%
Mkt Cap 13.945B
Industry Drug Manufacturers—Specialty & Generic
4.3400
+0.46%
Mkt Cap 539.395M
Industry Drug Manufacturers—Specialty & Generic
36.31
+1.63%
Mkt Cap 42.282B
Industry Drug Manufacturers—Specialty & Generic
5.57
+0.09%
Mkt Cap 665.598M
Industry Drug Manufacturers—Specialty & Generic
1.1450
+3.15%
Mkt Cap 514.197M
Industry Drug Manufacturers—Specialty & Generic
1.6900
-2.31%
Mkt Cap 7.534M
Industry Drug Manufacturers—Specialty & Generic
3.4850
+2.20%
Mkt Cap 206.056M
Industry Drug Manufacturers—Specialty & Generic
Company Insights: HIMS
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: HIMS
View MoreLowering target price to $25.00
HIMS & HERS HEALTH INC has an Investment Rating of HOLD; a target price of $25.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $27.00
HIMS & HERS HEALTH INC has an Investment Rating of HOLD; a target price of $27.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetWith Legal Overhang Behind, Hims Looks To Drive Growth via Novo Partnership and International Push
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
RatingPrice TargetRaising target price to $28.00
HIMS & HERS HEALTH INC has an Investment Rating of HOLD; a target price of $28.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target